
    
      This trial will involve diabetic patients with foot ulcers who meet the inclusion/exclusion
      criteria. At least 200 patients aged 45-80yrs will be enrolled in the study and randomly
      allocated to receive the active drug or the placebo in indistinguishable formulations. After
      2 months closure rate of the ulcer will be evaluated.
    
  